ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 40908696

Precision Enzyme: Targeted Drug Discovery in Neurodegenerative Disorders.

Paul S and 2 others. Protein Pept Lett, 2025. Cited by 2 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Precision Enzyme: Targeted Drug Discovery in Neurodegenerative Disorders. Papers, record 40908696. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40908696

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Precision Enzyme: Targeted Drug Discovery in Neurodegenerative Disorders.
PubMed
Journal
Protein Pept Lett
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2026-02-02
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Paul SSampriti
2Tiwari PPrashant
3Dubey SSonal

Source PubMed

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Drug DiscoveryMajor topic
Neurodegenerative DiseasesMajor topic
Enzyme InhibitorsMajor topic
Humans
Molecular Docking Simulation
Animals

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References110

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135,163,773A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics.Int J Mol Sci2022https://conductscience.org/library/papers/35163773PubMed
328,401,333Interactions of pathological proteins in neurodegenerative diseases.Acta Neuropathol2017https://conductscience.org/library/papers/28401333PubMed
436,430,432Alzheimer's Disease: Treatment Strategies and Their Limitations.Int J Mol Sci2022https://conductscience.org/library/papers/36430432PubMed
532,165,850Current and Future Treatments in Alzheimer Disease: An Update.J Cent Nerv Syst Dis2020https://conductscience.org/library/papers/32165850PubMed
632,755,952Overcoming the blood-brain barrier in neurodegenerative disorders and brain tumours.IET Nanobiotechnol2020https://conductscience.org/library/papers/32755952PubMed
730,323,170Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference.Nat Commun2018https://conductscience.org/library/papers/30323170PubMed
830,190,701Application of Precision Medicine in Neurodegenerative Diseases.Front Neurol2018https://conductscience.org/library/papers/30190701PubMed
938,003,309From Recognition to Remedy: The Significance of Biomarkers in Neurodegenerative Disease Pathology.Int J Mol Sci2023https://conductscience.org/library/papers/38003309PubMed
1036,260,224The Emerging Roles of E3 Ligases and DUBs in Neurodegenerative Diseases.Mol Neurobiol2023https://conductscience.org/library/papers/36260224PubMed
1132,390,854Histone Deacetylases Inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronal Differentiation.Front Pharmacol2020https://conductscience.org/library/papers/32390854PubMed

1 to 10 of 110

See all 110 references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42,981,378Identification and validation of biomarkers associated with mitochondrial dynamics dysfunction in Parkinson's disease based on GEO datasets.PLoS One2026https://conductscience.org/library/papers/42981378PubMed
42,682,425Increased serum fibroblast growth factor 2 levels, altered peripheral blood inflammatory indicators and their ratios in amyotrophic lateral sclerosis: a clinical exploratory study.Front Neurol2026https://conductscience.org/library/papers/42682425PubMed
41,907,306Next-generation Janus kinase inhibitors: Integrating synthetic innovation, structural biology, and computational design for precision drug discovery.Pharm Sci Adv2026https://conductscience.org/library/papers/41907306PubMed

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40908696

GET https://conductscience.org/api/papers/v1/40908696/references?page=2

API referenceFor AI assistants